Human Semaphorin 6D Alexa Fluor® 750-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB2095S
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Ser22-His660
Accession # Q8NFY4
Specificity
Clonality
Host
Isotype
Applications
Western Blot
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
Background: Semaphorin 6D
Semaphorin 6D (Sema6D) is a ~130-135 kDa member of the Semaphorin family of axon guidance molecules (1-3). The four known Class 6 semaphorins are type I transmembrane glycoproteins that share ~40% amino acid (aa) identity and exhibit neuropilin-independent binding to specific plexin A receptors (1, 2). Sema6D is expressed in the cardiac tube and within the brain and spinal cord during development (2-5). It shows broad expression postnatally, including neurons, lymphocytes, dendritic cells and osteoclasts (5-8). Brain, kidney, placenta, and cardiac and skeletal muscles show highest mRNA expression (2, 5). The primary human Sema6D isoform (1073 aa) includes a 21 aa signal sequence, a 642 aa extracellular domain (ECD) including Sema and PSI domains, a 21 aa transmembrane sequence and a 390 aa cytoplasmic portion. The ECD of this isoform shares 96%, 96%, 98%, 98% and 97% aa identity with corresponding mouse, rat, bovine, equine and canine sequences, respectively. Alternate splicing creates isoforms of 1054, 1030, 1017, 1011 and 998 that lack sequences between aa 570 and 644 and/or contain a 13 aa insert after aa 549; all variations affect the PSI domain (2, 5). An isoform of 476 aa is truncated after the Sema domain (2). All Sema6D isoforms are present in the brain, but are differentially expressed elsewhere (2, 5). In the developing brain, both Sema6D and Sema6C are co-expressed with Plexin A1 and interact differentially to guide proprioceptive peripheral neurons by repulsion (4). Sema6D is essential for morphogenesis of the cardiac ventricle in the chick, signaling both forward through Plexin A1 and in reverse through Sema6D (3, 9). Sema6D mediates survival and anchorage-independent growth of malignant pleural mesothelioma (10) It is active in immune responses by Sema6D+ T cell stimulation of dendritic cells, and in bone homeostasis by engaging osteoclast Plexin A1 (6-8). In all these settings, Sema6D acts through a complex of Plexin A1 with receptor tyrosine kinases such as VEGF R2 (3, 6-10).
Alternate Names
Gene Symbol
UniProt
Additional Semaphorin 6D Products
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only